| Name | Title | Contact Details |
|---|---|---|
Craig Thomas |
Chief Technology Officer | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Selfbook makes booking reservations and managing guests and payments easy. Switch your hotel to this incredible software today!
Cloud Storage Security is a company that provides malware scanning and data classification for Amazon S3, allowing customers to safely share files across critical applications, services, and devices within AWS S3.
Emergys is an industry leading Business Transformation Service provider focused on helping our partners and clients architect and implement strategies that utilize the emerging technologies. With our diverse expertise and capabilities, we help clients
AI Solutions for Business, Demand Prediction, Dynamic Pricing & Purchase Recommendation Instagram- AnalyticsToGo LinkedIn- Analytics2Go Facebook- Analytics2Go